Issue 56

Enhancing the accessibility of psychedelic healthcare

To strengthen the adoption of psychedelic-assisted therapies, drug developers are striving to minimise their cost – with shorter lasting tryptamines.

Psilocybin can induce altered states of consciousness for over ten hours, during which time patients need to be supervised by trained practitioners. DMT and 5-MeO-DMT have much shorter onset and offset times, enabling treatments in under 90 minutes.

UK-based Small Pharma and Beckley Psytech are conducting clinical trials with DMT and 5-MeO-DMT to treat major depressive disorder and treatment-resistant depression.

PSYCH spoke with Beckley Psytech’s Chief Scientific Officer, Stephen Wooding, and Small Pharma’s Chief Medical and Scientific Officer, Carol Routledge, on streamlining psychedelic-assisted therapy.

Read More

MDMA AND PSYCHOTHERAPY IN COMBINATION COULD BE USED TO TREAT ALCOHOLISM

Scientists behind the Bristol Imperial study hope MDMA-assisted therapy could help process the trauma behind alcoholism.

Read More

PSYCHEDELIC THERAPY IS POISED TO REVOLUTIONISE HEALTHCARE. CAN VR ACCELERATE IT?

In an effort to improve the accessibility of psychedelic medicines, companies are exploring digital solutions.

Read More

BUSINESS AND INVESTMENT

Tattarang invests AU$5m in Emyria to accelerate MDMA research.

Psychedelics stocks were all the rage a year ago. What happened?

Inside the race to create a two-hour psychedelic-therapy experience.

HAVN imports psilocybin from Jamaica into Canada.

COMPASS granted fifth patent for crystalline psilocybin.

Numinus to trade on OTC under NUMIF.

Love Pharma signs LOI to acquire MicroDoz Therapy.

Filament to license drug candidate to EntheoTech for clinical trials.

Wuhan General cancels 5,000,000 common shares.

Pasithea launches at-home ketamine treatments.

FDA requests changes to Tryp’s Phase II trial.

Entheon provides update on upcoming DMT clinical trial.

PharmaTher applies for orphan drug designation for ketamine treatment.

Biomind Labs develops DMT and 5-MeO-DMT nasal gel.

PsyBio files manufacturing patent applications.

Bexson expands ketamine development to target major depressive disorder.

Braxia Scientific CEO joins KetaMD in advisory capacity.

Small Pharma appoints Paul Maier as Independent Director.

SCIENCE AND RESEARCH

Blossom research briefing: microdosing and neural flexibility.

Is the UK an ideal location to run psychedelic trials?

Psilocybin may show therapeutic promise.

Psilocybin targets mechanism for cognitive impairment in alcoholism.

Yale researchers win US$2m to study ketamine for depression.

The effect of ketamine on preventing postpartum depression.

What effect will psilocybin have on the treatment of depression?

How psychedelic drugs are helping veterans with PTSD and depression.

Study finds psychedelic microdosing improves mental health.

I have ADHD and was scared of psychedelics, then I found myself eating magic truffles.

Five genes that may affect your reaction to psychedelic drugs

The Psychedelics as Medicine Report: Third Edition was powered by Blossom, the psychedelic industry’s largest database of market intelligence.

Blossom supports the development of the sector by providing data on companies, their research and clinical trials, empowering operators and policymakers to make informed decisions.

Subscribe to the newsletter

REGULATION AND LEGISLATION

Texas governor advocates for legislation change to enable psychedelics research.

Partner with us